Skip to main content
Journal cover image

Initial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program.

Publication ,  Journal Article
Keir, ST; Morton, CL; Wu, J; Kurmasheva, RT; Houghton, PJ; Smith, MA
Published in: Pediatr Blood Cancer
September 2012

Pazopanib is an oral angiogenesis inhibitor targeting vascular growth factor receptor-1, -2, and -3, platelet derived growth factor receptor-α, platelet derived growth factor receptor-β, and KIT that has demonstrated activity against a variety of adult cancer xenografts. Pazopanib was tested against a panel of pediatric rhabdomyosarcoma and Ewing sarcoma xenografts at a dose of 108 mg/kg/day or 100 mg/kg twice daily, administered orally for 28 days. While no objective responses were observed, pazopanib induced statistically significant differences in event-free survival compared to controls in approximately one-half of the sarcoma xenograft models tested. Though well tolerated, pazopanib showed limited activity against the sarcoma models evaluated, with the best tumor responses being growth delay.

Duke Scholars

Published In

Pediatr Blood Cancer

DOI

EISSN

1545-5017

Publication Date

September 2012

Volume

59

Issue

3

Start / End Page

586 / 588

Location

United States

Related Subject Headings

  • Xenograft Model Antitumor Assays
  • Vascular Endothelial Growth Factors
  • Sulfonamides
  • Sarcoma, Ewing
  • Rhabdomyosarcoma
  • Receptor, Platelet-Derived Growth Factor beta
  • Pyrimidines
  • Protein Kinase Inhibitors
  • Oncology & Carcinogenesis
  • Mice, SCID
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Keir, S. T., Morton, C. L., Wu, J., Kurmasheva, R. T., Houghton, P. J., & Smith, M. A. (2012). Initial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer, 59(3), 586–588. https://doi.org/10.1002/pbc.24016
Keir, Stephen T., Christopher L. Morton, Jianrong Wu, Raushan T. Kurmasheva, Peter J. Houghton, and Malcolm A. Smith. “Initial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program.Pediatr Blood Cancer 59, no. 3 (September 2012): 586–88. https://doi.org/10.1002/pbc.24016.
Keir ST, Morton CL, Wu J, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2012 Sep;59(3):586–8.
Keir, Stephen T., et al. “Initial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program.Pediatr Blood Cancer, vol. 59, no. 3, Sept. 2012, pp. 586–88. Pubmed, doi:10.1002/pbc.24016.
Keir ST, Morton CL, Wu J, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2012 Sep;59(3):586–588.
Journal cover image

Published In

Pediatr Blood Cancer

DOI

EISSN

1545-5017

Publication Date

September 2012

Volume

59

Issue

3

Start / End Page

586 / 588

Location

United States

Related Subject Headings

  • Xenograft Model Antitumor Assays
  • Vascular Endothelial Growth Factors
  • Sulfonamides
  • Sarcoma, Ewing
  • Rhabdomyosarcoma
  • Receptor, Platelet-Derived Growth Factor beta
  • Pyrimidines
  • Protein Kinase Inhibitors
  • Oncology & Carcinogenesis
  • Mice, SCID